Ubs Group Ag Verrica Pharmaceuticals Inc. Transaction History

Ubs Group Ag

$528 Billion
Q1 2025

A detailed history of Ubs Group Ag transactions in Verrica Pharmaceuticals Inc. stock. As of the latest transaction made, Ubs Group Ag holds 790,163 shares of VRCA stock, worth $6.28 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

790,163

Previous 174,062 353.95%

Holding current value

$6.28 Million

Previous $1.38 Million 354.16%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	BUY	N/A	616,101 Added 353.95%	790,163 $6.28 Million
Q4 2024 Feb 14, 2025	BUY	N/A	164,455 Added 1711.82%	174,062 $1.38 Million
Q3 2024 Nov 14, 2024	BUY	$7.95 - $7.95 $25,948 - $25,948	3,264 Added 51.46%	9,607 $76,000
Q2 2024 Aug 13, 2024	SELL	$5.89 - $9.56 $94,175 - $152,854	-15,989 Reduced 71.6%	6,343 $46,000
Q1 2024 May 13, 2024	SELL	$4.74 - $6.81 $9,266 - $13,313	-1,955 Reduced 8.05%	22,332 $132,000
Q4 2023 Feb 09, 2024	BUY	$2.93 - $7.32 $38,561 - $96,338	13,161 Added 118.29%	24,287 $177,000
Q3 2023 Nov 09, 2023	SELL	$3.75 - $7.46 $6,885 - $13,696	-1,836 Reduced 14.16%	11,126 $43,000
Q2 2023 Aug 11, 2023	BUY	$5.32 - $6.79 $59,637 - $76,115	11,210 Added 639.84%	12,962 $74,000
Q1 2023 May 12, 2023	SELL	$2.88 - $8.51 $460 - $1,361	-160 Reduced 8.37%	1,752 $11,000
Q4 2022 Feb 08, 2023	SELL	$2.09 - $3.39 $7,519 - $12,197	-3,598 Reduced 65.3%	1,912 $5,000
Q3 2022 Nov 10, 2022	BUY	$2.17 - $4.3 $4,550 - $9,017	2,097 Added 61.44%	5,510 $16,000
Q2 2022 Aug 10, 2022	BUY	$1.81 - $8.93 $1,091 - $5,384	603 Added 21.46%	3,413 $7,000
Q1 2022 May 16, 2022	SELL	$7.59 - $9.49 $11,787 - $14,737	-1,553 Reduced 35.59%	2,810 $23,000
Q4 2021 Feb 14, 2022	BUY	$9.1 - $13.36 $4,704 - $6,907	517 Added 13.44%	4,363 $40,000
Q3 2021 Nov 15, 2021	SELL	$9.55 - $13.96 $36,194 - $52,908	-3,790 Reduced 49.63%	3,846 $48,000
Q2 2021 Aug 13, 2021	SELL	$9.77 - $15.33 $22,324 - $35,029	-2,285 Reduced 23.03%	7,636 $86,000
Q1 2021 May 12, 2021	BUY	$10.51 - $17.46 $40,085 - $66,592	3,814 Added 62.45%	9,921 $150,000
Q4 2020 Feb 11, 2021	BUY	$7.41 - $12.63 $22,074 - $37,624	2,979 Added 95.24%	6,107 $71,000
Q3 2020 Nov 12, 2020	SELL	$6.16 - $10.3 $25,970 - $43,424	-4,216 Reduced 57.41%	3,128 $24,000
Q2 2020 Jul 31, 2020	SELL	$9.02 - $15.12 $32,832 - $55,036	-3,640 Reduced 33.14%	7,344 $81,000
Q1 2020 May 01, 2020	SELL	$7.14 - $16.86 $55,192 - $130,327	-7,730 Reduced 41.31%	10,984 $120,000
Q4 2019 Feb 14, 2020	BUY	$13.08 - $17.43 $62,260 - $82,966	4,760 Added 34.11%	18,714 $298,000
Q3 2019 Nov 14, 2019	BUY	$8.65 - $14.81 $83,074 - $142,235	9,604 Added 220.78%	13,954 $206,000
Q2 2019 Aug 14, 2019	BUY	$7.1 - $11.62 $15,605 - $25,540	2,198 Added 102.14%	4,350 $50,000
Q1 2019 May 14, 2019	SELL	$7.95 - $14.07 $15,931 - $28,196	-2,004 Reduced 48.22%	2,152 $24,000
Q4 2018 Feb 14, 2019	BUY	$6.75 - $16.12 $5,244 - $12,525	777 Added 22.99%	4,156 $34,000
Q3 2018 Nov 14, 2018	BUY	$13.94 - $19.88 $45,611 - $65,047	3,272 Added 3057.94%	3,379 $55,000
Q2 2018 Aug 14, 2018	BUY	$17.5 - $20.34 $1,872 - $2,176	107 New	107 $2,000

Others Institutions Holding VRCA

# of Institutions

Shares Held

20.3M

Call Options Held

Put Options Held

View Full List

About Verrica Pharmaceuticals Inc.

Ticker VRCA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,094,100
Market Cap $327M
Description
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and w...

More about VRCA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account